Pakistan Medicines & Pharma IntelligenceMedicine data  •  Company portfolios  •  Price records
MedInfoBaseMedicines · Evidence · Intelligence
Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

Macter International Limited

Pharmaceutical manufacturer · Pakistan

Database-driven profile Portfolio, price and regulatory-source intelligence derived from MedInfoBase records.
ShareSend this page
Regulatory & corporate identity

Company profile

Not yet verified
Company type
Pharmaceutical manufacturer
DRAP-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000141 211 linked products · source seen 10 Aug 2026 View source ↗
DML 000641 37 linked products · source seen 10 Aug 2026 View source ↗
Location intelligence

Company location

Google Maps
Exact site not yet verified

MedInfoBase will not invent a factory or office location. The map appears after a sourced address, Place ID or verified embed URL is added.

Open in Google Maps ↗ The Google Maps search link uses the company name and available city/country context; it is not presented as a verified premises pin.
Intelligence snapshot

Portfolio at a glance

Not sales data · current MedInfoBase database view
Rx248product presentations
G91generic molecules
DF11dosage-form groups
TA14therapeutic areas
PKR248current price records
REG201registration numbers
Data coverage

How complete is this profile?

Current price coverage100%
products with a current official price
Source-linked coverage100%
products linked back to a source record
Unit-price parse coverage94%
priced packs safely normalized per unit
Comparable-market coverage79%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixMacter International LimitedShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/macter-international-limitedGenerated 10 Aug 2026Anti-infectives111 · 45%Cardiovascular27 · 11%Hematology & thrombosis26 · 10%Respiratory & allergy16 · 6%Endocrine & metabolic15 · 6%Gastrointestinal & hepatology10 · 4%Oncology & immunology9 · 4%Other therapeutic areas34 · 14%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioMacter International LimitedDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/macter-international-limitedGenerated 10 Aug 2026248presentationsTablet113 · 46%Injection64 · 26%Suspension24 · 10%Capsule17 · 7%Inhalation11 · 4%Infusion6 · 2%Other forms13 · 5%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent-Market Price Position

Shows whether safely comparable products are below, near or above the market median unit price.

Equivalent-Market Price PositionMacter International LimitedCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/macter-international-limitedGenerated 10 Aug 2026197comparable productsBelow market median27 · 14%Near market median87 · 44%Above market median83 · 42%Company median price position+3.5%Lowest-price equivalents20Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsMacter International LimitedCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/macter-international-limitedGenerated 10 Aug 2026Nabiqasim Industries (Pvt) Ltd.,48 shared53% overlapM/s. Genix Pharma (Pvt) Ltd.46 shared51% overlapBio-Labs(Pvt) Ltd43 shared47% overlapNeutro Pharma (Pvt.) Ltd.,42 shared46% overlapBosch Pharmaceuticals (Pvt) Ltd.41 shared45% overlapMediate Pharmaceutical Pvt Ltd41 shared45% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Formulation footprint

Dosage forms

Tablet113 products
Injection64 products
Suspension24 products
Capsule17 products
Inhalation11 products
Infusion6 products
Syrup4 products
Vaccine4 products
Drops3 products
Cream1 products
Solution1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median2714% of comparable products
Near market median87within ±5% of median
Above market median8342% of comparable products
Lowest-price equivalents20ties included
Company median price position +3.5% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Regulatory & price activity

Observed database signals

Registration numbers201
Price-history records291
Products with price history37
Source records with multiple versions0
Latest MedInfoBase verification9 Aug 2026
Latest effective price date29 Jul 2026
Latest source observation10 Aug 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Sponsored company campaign area · advertising must be clearly disclosed
Complete company portfolio

Products and presentations

248 results
Reset
BrandGenericStrengthFormPackRegistrationOfficial priceUnit priceMarket position
Maxima Cefixime 200 mg Tablet 10's 055842 PKR 669.68 PKR 66.97/tablet Near median
Maxima Cefixime 100 mg/5 mL Suspension 30ml 029787 PKR 330.39 PKR 11.01/mL 5% above median
Maxima Cefixime 400 mg Capsule 5's 029786 PKR 592.03 PKR 118.41/capsule Near median
Maxima DS Cefixime 200 mg/5 mL Suspension 30ml 044355 PKR 404.32 PKR 13.48/mL Near median
Mazlero Rivaroxaban 15 mg Tablet 7's 105442 PKR 5,196.51 PKR 742.36/tablet 5% above median
Mazlero Rivaroxaban 15 mg Tablet 10's 105442 PKR 7,051.08 PKR 705.11/tablet Near median
Mazlero Rivaroxaban 20 mg Tablet 10's 105441 PKR 8,925.84 PKR 892.58/tablet Near median
Mazlero Rivaroxaban 20 mg Tablet 7's 105441 PKR 6,576.18 PKR 939.45/tablet 5% above median
Mazlero Rivaroxaban 15 mg Tablet 14's 105442 PKR 9,871.52 PKR 705.11/tablet Near median
Mazlero Rivaroxaban 10 mg Tablet 10's 105443 PKR 5,522.14 PKR 552.21/tablet Near median
Mazlero Rivaroxaban 20 mg Tablet 14's 105441 PKR 12,496.18 PKR 892.58/tablet Near median
Mazlero Rivaroxaban 10 mg Tablet 30's 105443 PKR 16,228.33 PKR 540.94/tablet Near median
Mclevo Levofloxacin 750 mg Tablet 10's 053472 PKR 1,032.66 PKR 103.27/tablet 11% above median
Mclevo Levofloxacin 500 mg Tablet 10's 044426 PKR 859.17 PKR 85.92/tablet 9% above median
Mclevo Levofloxacin 250 mg Tablet 10's 044425 PKR 516.32 PKR 51.63/tablet 9% above median
Meadow Fexofenadine 60 mg Tablet 10 033863 PKR 135.63 PKR 13.56/tablet 15% above median
Meadow Fexofenadine 180 mg Tablet 10 033865 PKR 369.89 PKR 36.99/tablet 16% above median
Meadow Fexofenadine 120 mg Tablet 10 033864 PKR 286.04 PKR 28.60/tablet 16% above median
Mellistin Colistimethate sodium 1 MIU Injection 1's 107383 PKR 3,616.81 PKR 3,616.81/vial/unit 201% above median
Midolam Midazolam 1 mg/mL Solution for injection 10 x 5 ml 022825 PKR 1,618.15 PKR 32.36/mL No comparator
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and DRAP-source records. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.